Literature DB >> 10706884

A new ETV6/TEL partner gene, ARG (ABL-related gene or ABL2), identified in an AML-M3 cell line with a t(1;12)(q25;p13) translocation.

Y Iijima1, T Ito, T Oikawa, M Eguchi, M Eguchi-Ishimae, N Kamada, K Kishi, S Asano, Y Sakaki, Y Sato.   

Abstract

The ETV6/TEL gene has been reported to fuse to PDGFRbetab MDS1/EVI1, BTL, ACS2, STL, JAK2, ABL, CDX2, TRKC, AML1, and MN1. Among them, PDGFRbeta, ABL, JAK2, and TRKC are tyrosine kinases (TK). We identified a novel ETV6 partner gene, ARG (ABL-related gene or ABL2), another TK gene in a cell line established from a patient with acute myelogenous leukemia (AML-M3) with a t(15;17)(q22;q11.2) and a t(1;12)(q25;p13), which has the remarkable feature to differentiate to mature eosinophils in culture with all-trans retinoic acid and cytokines. The ETV6/ARG transcripts consisted of exon 1 to 5 of ETV6 and the 3' portion of ARG starting from exon 1B or exon 2, resulting in an open reading frame for a fusion protein consisting of the entire PNT oligomerization domain of ETV6 and all of the functional domains of ARG including the TK domain. This is the same protein structure as identified in the other ETV6 TK fusion proteins. The reciprocal ARG/ETV6 transcript was not expressed, and the normal ETV6 allele was not deleted or rearranged. Although the ABL is known to be involved in various human malignancies, ARG has not been involved in human malignancies despite its high homology to ABL. Thus, this is the first report showing involvement of ARG in human leukemia. The ETV6/ARG protein may be involved in the unique differentiation capacity of this cell line. (Blood. 2000;95:2126-2131)

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10706884

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  22 in total

1.  Identification of uncommon chromosomal aberrations in the neuroglioma cell line H4 by spectral karyotyping.

Authors:  D Krex; B Mohr; M Hauses; G Ehninger; H K Schackert; G Schackert
Journal:  J Neurooncol       Date:  2001-04       Impact factor: 4.130

2.  Two distinct phosphorylation pathways have additive effects on Abl family kinase activation.

Authors:  Keith Q Tanis; Darren Veach; Henry S Duewel; William G Bornmann; Anthony J Koleske
Journal:  Mol Cell Biol       Date:  2003-06       Impact factor: 4.272

3.  Structure of the ABL2/ARG kinase in complex with dasatinib.

Authors:  Byung Hak Ha; Mark Adam Simpson; Anthony J Koleske; Titus J Boggon
Journal:  Acta Crystallogr F Struct Biol Commun       Date:  2015-03-20       Impact factor: 1.056

Review 4.  ABL tyrosine kinases: evolution of function, regulation, and specificity.

Authors:  John Colicelli
Journal:  Sci Signal       Date:  2010-09-14       Impact factor: 8.192

5.  The acetyltransferase 60 kDa trans-acting regulatory protein of HIV type 1-interacting protein (Tip60) interacts with the translocation E26 transforming-specific leukaemia gene (TEL) and functions as a transcriptional co-repressor.

Authors:  Iver Nordentoft; Poul Jørgensen
Journal:  Biochem J       Date:  2003-08-15       Impact factor: 3.857

Review 6.  Abl tyrosine kinases in T-cell signaling.

Authors:  Jing Jin Gu; Jae Ryun Ryu; Ann Marie Pendergast
Journal:  Immunol Rev       Date:  2009-03       Impact factor: 12.988

7.  Activation of abl family kinases in solid tumors.

Authors:  Sourik S Ganguly; Rina Plattner
Journal:  Genes Cancer       Date:  2012-05

8.  Mutations in the SAM domain of the ETV6-NTRK3 chimeric tyrosine kinase block polymerization and transformation activity.

Authors:  Cristina E Tognon; Cameron D Mackereth; Aruna M Somasiri; Lawrence P McIntosh; Poul H B Sorensen
Journal:  Mol Cell Biol       Date:  2004-06       Impact factor: 4.272

9.  The TEL/ARG leukemia oncogene promotes viability and hyperresponsiveness to hematopoietic growth factors.

Authors:  Keiko Okuda; Yuko Sato; Yoshiaki Sonoda; James D Griffin
Journal:  Int J Hematol       Date:  2004-02       Impact factor: 2.490

Review 10.  Translocations in epithelial cancers.

Authors:  J Chad Brenner; Arul M Chinnaiyan
Journal:  Biochim Biophys Acta       Date:  2009-05-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.